NCT05879523

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effects of Food on the Pharmacokinetics of HRS-1893 Tablets After Single and Multiple Ascending Oral Doses in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Shandong Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this phase Ⅰ study is to evaluate the safety, tolerability and pharmacokinetics of HRS-1893 in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy

Conditions

• Obstructive Hypertrophic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	HRS-1893	subcutaneous, single dose, multiple doses
DRUG	Placebo	subcutaneous, single dose, multiple doses

Timeline

• Start date: 2023-06-05
• Primary completion: 2024-03-21
• Completion: 2024-03-21
• First posted: 2023-05-30
• Last updated: 2024-10-30

Locations

1 site across 1 country: China